`
`
`
`Paper No._______
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________
`
`BIODELIVERY SCIENCES INTERNATIONAL, INC.
`Petitioner
`
`v.
`
`RB PHARMACEUTICALS LIMITED
`Patent Owner
`_______________
`
`Case No. IPR2014-00325
`Patent 8,475,832
`_______________
`
`
`
`
`
`
`PETITIONER’S REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE
`
`
`
`
`
`
`
`
`
`
`
`
`
`ME1 20010336v.1
`
`
`
`Case IPR2014-000325
`
`As explained in the Motion to Exclude, the statements quoted by RB from
`
`Exhibit 2043 concern the difficulty in designing a film with seven elements recited
`
`in claims of the unrelated ‘019 patent, i.e., [1] thinness, [2] flexibility, [3] residence
`
`time, [4] adhesion, [5] bioerosion, [6] fast onset/within 30 minutes, and [7]
`
`directional delivery. Paper No. 35, at 4. As illustrated below, each of these
`
`elements is explicitly recited in claim 1 of the ‘019 patent:
`
`On the other hand, none of these seven elements is recited in the claims challenged
`
`in this proceeding, as illustrated by the following comparison of the independent
`
`
`
`claims:
`
`
`
`ME1 20010336v.1
`
`
`
`1
`
`
`
`Case IPR2014-000325
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`RB’s suggestion in its Opposition—that the claims challenged here
`
`somehow claim the same features as those recited in the ‘019 claims—highlights
`
`RB’s attempt to rewrite the challenged claims in this proceeding.
`
`For example, in its Motion to Exclude, BDSI correctly pointed out that the
`
`claims of the ‘019 patent share no common claim language with the claims
`
`challenged in this proceeding, except for “film” and “profile.” Paper No. 35, at 6.
`
`Rather than point to any claim language in common or any other relationship
`
`between the claims that would make Exhibit 2043 relevant here—neither of which
`
`exists—RB simply contends that the ‘019 patent and ‘832 patent are both directed
`
`to “a film dosage form providing a desired level of a pharmaceutical active to a
`
`subject via oral transmucosal absorption…” Paper No. 37, at 6.
`
`ME1 20010336v.1
`
`2
`
`
`
`Case IPR2014-000325
`
`This argument is troubling for at least two reasons. First, RB seems to
`
`suggest that if the specifications of two patents are directed to the same subject
`
`matter—which, in this case, they are not—their claimed subject matter is
`
`necessarily the same. There is no support for this contention.
`
`Second, in support of the alleged subject matter in common, RB quotes
`
`claim language from claim 1 of the ‘019 patent, but does not quote any language
`
`from the claims challenged in this proceeding. This is because, as illustrated
`
`above, the challenged claims in this proceeding do not recite any of the seven
`
`recited features at issue in Exhibit 2043.
`
`Obviously aware that the challenged claims do not recite any of these seven
`
`features, RB appears to ask this Board to ignore the fundamental principle of claim
`
`construction law by ignoring the claim language. Strikingly, RB contends that the
`
`fact that the ‘019 and ‘832 claims “might use different ‘language’ does not change
`
`[the] fact” that the two patents are allegedly directed to the same thing. Paper No.
`
`37, at 6-7. However:
`
`The claim is a statutory requirement, prescribed for the very purpose
`
`of making the patentee define precisely what his invention is; and it is
`
`unjust to the public, as well as an evasion of the law, to construe it in a
`
`manner different from the plan import of its terms.
`
`White v. Dunbar, 119 U.S. 47, 52 (1886). RB seems to be asking the Board to
`
`import multiple limitations into the recited claim language in the ‘832 challenged
`3
`
`ME1 20010336v.1
`
`
`
`Case IPR2014-000325
`
`claims in order to find some connection between these claims and those of the ‘019
`
`patent. No such connection exists.
`
`Accordingly, for the reasons explained above and in BDSI’s Motion to
`
`Exclude (Paper No. 35), RB’s Exhibit 2043 should be excluded as inadmissible
`
`under Federal Rules of Evidence 401 and 403.
`
`
`
`Dated: March 17, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`By: /Danielle L. Herritt/
`Danielle L. Herritt (Reg. No. 43,670)
`Kia L. Freeman (Reg. No. 47,577)
`
`ME1 20010336v.1
`
`4
`
`
`
`Case IPR2014-000325
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing PETITIONER’S
`
`REPLY IN SUPPORT OF ITS MOTION TO EXCLUDE, including this
`
`Certificate of Service, was electronically served on March 17, 2015 by transmitting
`
`a copy to lead counsel James Bollinger at james.bollinger@troutmansanders.com
`
`and to backup counsel Daniel Ladow at daniel.ladow@troutmansanders.com in
`
`accordance with the consent set forth in RB Third Amended Mandatory Notice
`
`Information.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`
`/Danielle L. Herritt/
`
`
`
`
`
`
`
`
`
`Danielle L. Herritt
`
`Registration No. 43,670
`
`Attorney for the Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ME1 20010336v.1
`
`5
`
`